Founder of Batu Biologics Expands Involvement as Chief Scientific Officer
Thomas Ichim, PhD, will oversee the scientific development of the ValloVax therapeutic program
Batu Biologics, an immuno-oncology company dedicated to the development of its tumor-angiogenesis targeting immune therapy, ValloVax™, announced today the appointment of Thomas Ichim, PhD, to the position of Chief Scientific Officer.
